Holen Sie sich die Stockscreener-App
0.4633
10.70%
0.0633
Schlusskurs vom Vortag:
$0.40
Offen:
$0.409
24-Stunden-Volumen:
1.79M
Relative Volume:
0.24
Marktkapitalisierung:
$6.36M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.93M
KGV:
-0.00174
EPS:
-266.137
Netto-Cashflow:
$-15.87M
1W Leistung:
+62.50%
1M Leistung:
-36.12%
6M Leistung:
-97.72%
1J Leistung:
-97.44%
1-Tages-Spanne:
$0.406
$0.48
1-Wochen-Bereich:
$0.2784
$0.4681
52-Wochen-Spanne:
$0.2196
$66.33
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Firmenname
Transcode Therapeutics Inc
Sektor
Branche
Telefon
857-301-6857
Adresse
6 LIBERTY SQUARE, BOSTON
Vergleichen Sie RNAZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
0.4647 | 6.36M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.50 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
590.85 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
597.20 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.74 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.04 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Transcode Therapeutics Inc Aktie (RNAZ) Neueste Nachrichten
(RNAZ) Trading Signals - news.stocktradersdaily.com
What’s The Deal With TransCode Therapeutics Inc (NASDAQ: RNAZ)? - Stocksregister
TransCode Therapeutics Faces Crucial Reverse Split Decision as Special Meeting Falls Short of Quorum - Stock Titan
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting - Yahoo Finance
What is the investor’s view on TransCode Therapeutics Inc (RNAZ)? - uspostnews.com
HC Wainwright Issues Pessimistic Forecast for RNAZ Earnings - The AM Reporter
All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy - MSN
HC Wainwright Cuts TransCode Therapeutics (NASDAQ:RNAZ) Price Target to $10.00 - Defense World
Research Analysts Offer Predictions for RNAZ Q1 Earnings - Defense World
Transcode Therapeutics stock hits 52-week low at $0.34 By Investing.com - Investing.com South Africa
Transcode Therapeutics stock hits 52-week low at $0.34 - Investing.com
An Open Letter to Shareholders of TransCode Therapeutics, Inc. Asking Stockholders to Vote FOR the Proposal to Authorize a Reverse Stock Split if Necessary - Yahoo Finance
Transcode Therapeutics, Inc. SEC 10-K Report - TradingView
TransCode Therapeutics Inc (NASDAQ: RNAZ) Stock: Bulls Should Watch This - stocksregister.com
Wynn Resorts Ltd (WYNN) Shares Plummet Below 1-Year High - News Heater
Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) PT at $76.29 - Defense World
RNAZ stock touches 52-week low at $0.43 amid sharp annual decline By Investing.com - Investing.com South Africa
RNAZ stock touches 52-week low at $0.43 amid sharp annual decline - Investing.com
TransCode Therapeutics Inc’s Stock Price Plummeted Recently, But There Might Be Trouble Ahead - stocksregister.com
Best Penny Stocks Under $1 to Buy Now: April 2025 Watchlist - timothysykes.com
TransCode Therapeutics Delays Annual Report Filing - TipRanks
TransCode Therapeutics (RNAZ) Expected to Announce Earnings on Monday - Defense World
Emerging Tech QuartetPRSO, LXRX, PRTG, RNAZDrive - openPR.com
Pre-market Movers: PRTG, RNAZ, PTIX, LGMK... - RTTNews
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
TransCode Therapeutics stock slides after announces to raise $10M securities offering - MSN
(RNAZ) Investment Analysis - news.stocktradersdaily.com
Small Cap Stocks To Follow TodayMarch 23rd - MarketBeat
TransCode Therapeutics, Inc. Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial Withttx-Mc138 - MarketScreener
TransCode Therapeutics Starts Dosing for Experimental Cancer Treatment in Early Trial - Marketscreener.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Cancer Drug Trial Hits Major Milestone: Zero Toxicity as Doses Increase 50% - Stock Titan
TransCode's $10M Capital Raise Powers Critical Cancer Drug Clinical Trials - Stock Titan
Biotech Alert: Searches spiking for these stocks today - TipRanks
Transcode Therapeutics stock hits 52-week low at $0.64 By Investing.com - Investing.com Australia
TransCode Therapeutics Announces $10M Stock And Warrant Offering - Nasdaq
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Transcode Therapeutics stock hits 52-week low at $0.64 - Investing.com India
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Transcode to sell 10.25M shares at 98c per share in registered direct offering - TipRanks
Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
TransCode Therapeutics Starts $10 Million Direct Offering of Stock, Warrants -March 24, 2025 at 03:42 am EDT - Marketscreener.com
$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - Stock Titan
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - PR Newswire
Small Cap Stocks To ResearchMarch 21st - MarketBeat
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
(RNAZ) Long Term Investment Analysis - Stock Traders Daily
HC Wainwright Reaffirms “Buy” Rating for TransCode Therapeutics (NASDAQ:RNAZ) - Defense World
RNAZ stock touches 52-week low at $0.69 amid sharp annual decline - Investing.com Canada
Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):